New publications
Preparations
Taflotan
Ophthalmic agent in the form of eye drops. Taflotan is intended for the treatment of patients with glaucoma. The drug is an analogue of prostaglandin.
Indications of the taflotana
The use of tuflotan is appropriate for lowering high intraocular pressure, which usually accompanies open-angle glaucoma and ocular hypertensive syndrome in adult practice.
As the main medicament, Taflotan can be used with insufficient dynamics after the initial treatment, as well as with intolerance or hypersensitivity to treatment with first line drugs.
As part of complex therapy, Taflotan is prescribed along with β-blockers.
Release form
Taflotan is an ophthalmic solution, packaged in 0.3 ml in special drip tubes. The number of tubes in the package - 10 pieces, in bags of foil.
The active ingredient is tafluprost, the content of which in one drop tube is 4.5 mcg.
The solution of Taflotan does not have a certain color, it is completely transparent.
Pharmacodynamics
Taflotan belongs to the fluorine-containing analogues of prostaglandin F 2α.
The bioactive metabolite of the drug is tafluprostic acid, the active and selective agonist of the prostanoid human receptor. Metabolite has affinity for the FP receptor, 12 times that of latanoprost.
According to the research, Taflotan reduces intraocular pressure, increasing the uveoscleral fluid flow.
The active ingredient of Taflotan has a qualitative effect on the processes of reducing intraocular pressure. The first effect is observed after 2-4 hours after the application of drops, and the maximum possible effect is manifested after 12 hours. The effect of the drug persists throughout the day.
In the course of the experiments it was found that Taflotan lowered the intraocular pressure by an average of 6-8 mm Hg. Compared with 7-9 mm Hg. Art. After the introduction of latanoprost. In comparison with timolol, the indices are as follows: 5-7 mm Hg. Art. And 4-6 mm Hg. Art. Respectively.
Pharmacokinetics
When a single drop of Tafflotan was applied to the conjunctiva of each eye overnight for eight days, the concentration content of tafluprost acid in the serum was minimal and the same - both on the first day and on the eighth day of the drug use.
The limiting concentration indices in the serum were detected 10 minutes after the application of the solution and decreased even before the completion of the first 60 minutes. The average concentration limit was the same on the first and on the eighth day, indicating an equivalent content of the medication during the first week of treatment.
Clinically significant differences in the systemic bioavailability of Taflotan preparations with and without a preservative have not been recorded.
There were no specific features in the distribution of the labeled solution in the iris and ciliary body: this indicates a small affinity for the pigmentary substance melanin. During experiments that were performed using autoradiography, the maximum radioactivity was found in the cornea, eyelids, sclera, and iris. Outside the eye organ, radioactivity spread through the lacrimal apparatus, the upper sky, esophagus and digestive system, kidneys, and liver.
The binding of a metabolite with a plasma protein was 99% (with a concentration of a metabolite of 500 ng per ml).
Metabolism is performed by methods of glucuronidation or β-oxidation.
Excretion of Taflotan occurs to a lesser extent through the kidneys (up to 38%) and more to the calves (up to 58%).
Use of the taflotana during pregnancy
The specialists did not conduct research on the influence of Taflotan on the body of pregnant women and on the development of a future child. However, such studies were carried out on animals: it was discovered during the course of the study that Taflotan had reproductive toxicity. Proceeding from this, do not recommend this medication to patients who are expecting a child.
As for the use of Taflotan by women who are breastfeeding, rodent studies have demonstrated that the drug and its metabolites are absorbed into breast milk even with topical use of the drug. Therefore, Taflotan is not prescribed for patients in the lactation period.
Side effects of the taflotana
Clinical experiments were conducted, in which almost one and a half thousand patients took part. All of them were prescribed treatment with Taflotan in the form of a mono drug, or in combination with 0.5% Timolol. It was found that most often (in 13%) during treatment, the patients had reddening of the eyes. However, only 0.4% of patients had to stop treatment because of this.
Other observations of European and American specialists, which lasted two years, have demonstrated other possible side manifestations of Taflotan:
- pain in the head;
- ocular itching and pain;
- change the appearance of eyelashes (change in thickness, quantity, length, etc.);
- sensation of a foreign object in the eyes, increased teardrop (or vice versa, "dry eye");
- puffiness of the eyelids, increased fatigue of the eye organs, blepharitis, conjunctivitis, temporary deterioration of vision.
In rare cases, allergic reactions to medicament Taflotan were noted.
Dosing and administration
The standard amount of Taflotan is one drop of solution, which should be dripped under the conjunctiva of the affected eye organisus every night.
Do not use Taflotan more often than prescribed by your doctor, as this can lead to a decrease in the effectiveness of normalization of intraocular pressure.
One package of Taflotan is used for instillation in both eyes. If the dissected drug remains, it must be discarded.
If, during the application of drops, the solution of Taflotan is on the skin, it should be removed as far as possible in order to prevent a change in skin color.
If a patient needs to drip several ophthalmic medications, then between them, a time interval of 5-10 minutes should be maintained.
Interactions with other drugs
As a rule, we do not talk about medicinal interactions with Taflotan, since the systemic ingestion of a drug substance into the bloodstream is extremely low. Taking this into account, the specialists did not conduct accurate studies on possible pharmacological interactions.
Tests were conducted on the simultaneous use of Taflotan and Timolol. At the same time, no cross interactions were observed.
Storage conditions
Ophthalmic solution of Taflotan is kept in a packaged form, adhering to the temperature regime from +2 to +8 ° C, outside of the children's access.
After the packaging with Taplothane has been opened, the solution can be stored for no longer than one month, at temperatures up to + 25 ° C. If the use of droplets was a single shot, the remaining solution of Tafflotan should be discarded.